Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database

被引:4
作者
Chan, Hilary [1 ]
Zhang, Li [1 ]
Choti, Michael A. [2 ]
Kulke, Matthew [3 ]
Yao, James C. [4 ]
Nakakura, Eric K. [1 ]
Bloomston, Mark [5 ,6 ]
Benson, Al B. [7 ]
Shah, Manisha H. [5 ,6 ]
Strosberg, Jonathan R. [8 ]
Bergsland, Emily K. [1 ]
Van Loon, Katherine [1 ]
机构
[1] Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, 550 16th St,6th Floor,Box 3211, San Francisco, CA 94143 USA
[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA
[6] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA
[7] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
基金
美国医疗保健研究与质量局;
关键词
neuroendocrine tumors; recurrence; surveillance; guidelines; FOLLOW-UP; PROGNOSTIC-FACTORS; SURVIVAL; METASTASES; MANAGEMENT; STANDARDS; LIVER; CARE;
D O I
10.1097/MPA.0000000000001791
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective Current National Comprehensive Cancer Network guidelines for gastroenteropancreatic neuroendocrine tumors (GEPNETs) recommend complete (R0) surgical resection of the primary tumor and metastases, if feasible. However, large multicenter studies of recurrence patterns of GEPNETs after resection have not been performed. Methods Patients 18 years or older who presented to 7 participating National Comprehensive Cancer Network institutions between 2004 and 2008 with a new diagnosis of a small bowel, pancreas, or colon/rectum neuroendocrine tumor (NET) and underwent R0 resection of the primary tumor, and synchronous metastases, if present, were included in this analysis. Descriptive statistics and Kaplan-Meier estimates were used to calculate recurrence rates and time-associated end points, respectively. Results Of 294 patients with GEPNETs, 50% were male, 88% were White, and 99% had Eastern Cooperative Oncology Group performance status 0 to 1. The median age was 55 years (range, 20-90). The median follow-up time from R0 resection was 62.1 months. Recurrence rates were 18% in small bowel NETs (n = 110), 26% in pancreatic NETs (n = 141), and 10% in colon/rectum NETs (n = 50). The frequency of surveillance imaging was highly variable. Conclusions R0 resection was associated with variable risk of recurrence across subtypes. Further research to inform refinement of guidelines for the appropriate duration of surveillance after R0 resection is needed.
引用
收藏
页码:506 / 512
页数:7
相关论文
共 28 条
[1]   ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation [J].
Arnold, Rudolf ;
Chen, Yuan-Jia ;
Costa, Frederico ;
Falconi, Massimo ;
Gross, David ;
Grossman, Ashley B. ;
Hyrdel, Rudolf ;
Kos-Kudla, Beata ;
Salazar, Ramon ;
Ploeckinger, Ursula .
NEUROENDOCRINOLOGY, 2009, 90 (02) :227-233
[2]   Current concepts - Computed tomography - An increasing source of radiation exposure [J].
Brenner, David J. ;
Hall, Eric J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) :2277-2284
[3]   VALIDATION OF A COMBINED COMORBIDITY INDEX [J].
CHARLSON, M ;
SZATROWSKI, TP ;
PETERSON, J ;
GOLD, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (11) :1245-1251
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]   Pancreaticoduodenectomy and metastasectomy for metastatic pancreatic neuroendocrine tumors [J].
Chawla, Akhil ;
Williams, Richelle T. ;
Sich, Nicholas ;
Clancy, Thomas ;
Wang, Jiping ;
Ashley, Stanley ;
Pezzi, Christopher ;
Swanson, Richard .
JOURNAL OF SURGICAL ONCOLOGY, 2018, 118 (06) :983-990
[6]   Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? [J].
Chen, H ;
Hardacre, JM ;
Uzar, A ;
Cameron, JL ;
Choti, MA .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 187 (01) :88-92
[7]   Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States [J].
Dasari, Arvind ;
Shen, Chan ;
Halperin, Daniel ;
Zhao, Bo ;
Zhou, Shouhao ;
Xu, Ying ;
Shih, Tina ;
Yao, James C. .
JAMA ONCOLOGY, 2017, 3 (10) :1335-1342
[8]  
Edge S.B., 2010, AJCC cancer staging manual, V649
[9]   Long-term survival after surgical management of neuroendocrine hepatic metastases [J].
Glazer, Evan S. ;
Tseng, Jennifer F. ;
Al-Refaie, Waddah ;
Solorzano, Carmen C. ;
Liu, Ping ;
Willborn, Katherine A. ;
Abdalla, Eddie K. ;
Vauthey, Jean-Nicolas ;
Curley, Steven A. .
HPB, 2010, 12 (06) :427-433
[10]   68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis [J].
Graham, Michael M. ;
Gu, Xiaomei ;
Ginader, Timothy ;
Breheny, Patrick ;
Sunderland, John J. .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (09) :1452-1458